Topiramate decreases the salience of motivationally relevant visual cues among smokers with alcohol use disorder.

ABSTRACT:

Background

There is preliminary evidence that the anticonvulsant topiramate increases the likelihood of both smoking and alcohol abstinence among smokers with alcohol use disorder (AUD), but its therapeutic mechanism has not been determined. We used event-related potentials (ERPs) to evaluate topiramate's effect on the salience of drug-related, emotional, and neutral pictorial cues to identify whether one of its potential therapeutic mechanisms involves reduction of the salience of motivationally relevant cues.

Methods

Participants enrolled in a multisite clinical trial treating smokers with AUD were randomly assigned to receive placebo, low-dose topiramate (up to 125 mg/day), or high-dose topiramate (up to 250 mg/day), along with brief behavioral compliance enhancement trea

SUBMITTER: Robinson JD 

PROVIDER: S-EPMC8920769 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature